Sinitilimab is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. All registered phases are Phase 2. The sponsor with the most trials is Sun Yat-sen University (1). The most-studied condition is Esophageal Squamous Cell Carcinoma (ESCC).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma
NCT04989985 · ClinicalTrials.gov ↗ · Locally Advanced Gastroesophageal Junction Adenocarcinoma, Chemotherapy Effect
|
Phase 2 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | China |
|
Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer
NCT07751055 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)
|
Phase 2 | Recruiting | Sun Yat-sen University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Sun Yat-sen University | 1 |
| Sixth Affiliated Hospital, Sun Yat-sen University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Sinitilimab as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Sun Yat-sen University (1) and Sixth Affiliated Hospital, Sun Yat-sen University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Sinitilimab works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Sinitilimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Sinitilimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.